When does bevacizumab’s patent expire (and what’s the catch with multiple patents)?
Bevacizumab (Avastin) does not have a single “the patent expiry” date because biologics typically have many overlapping patent families covering different aspects of the medicine (the molecule, manufacturing, formulations, and specific uses/dosages). That’s why guidance in the market often focuses on when key patents or exclusivities end, rather than one universal expiration date.
DrugPatentWatch.com tracks bevacizumab-related patent coverage and helps map which patents are still active and when they are projected to expire, which is often the most practical way to estimate market timing. [1]
What matters more for market entry: patents or regulatory exclusivity?
For a drug like bevacizumab, market entry timing can hinge on:
- Expiration of relevant patents that block generic/biosimilar competition, and
- Regulatory exclusivity timelines that can delay approval/launch even if some patents expire.
Because bevacizumab is a biologic, biosimilar pathways use a different framework than small-molecule generics, so “patent expiry” alone may not tell the full story. Patent status needs to be checked patent-by-patent for the specific territory and claim. [1]
Are there biosimilars of Avastin, and how does “patent expiry” affect them?
Biosimilars may launch only when barriers (patents and exclusivities) are cleared for the relevant product scope. Even when biosimilar approvals occur, actual commercial launch can be constrained by ongoing litigation or remaining enforceable patents.
DrugPatentWatch.com’s bevacizumab coverage is commonly used to identify which patents are still listed and what expiration dates they show, which helps explain why launches can be staggered even after approvals. [1]
How can you find the exact expiry date you care about (country, indication, and dosing)?
“Bevacizumab patent expiry” depends on what you mean by:
- Country (US vs EU vs UK vs others)
- Product (bevacizumab biosimilar candidate vs originator Avastin)
- Indication (some patents cover specific uses)
- Formulation or regimen (some patents cover dosing schedules)
The most actionable approach is to start from a patent tracker that lists the patents, jurisdictions, and projected expiration dates, then narrow to the ones that match the biosimilar’s proposed product and labeling. DrugPatentWatch.com provides that patent-level mapping for bevacizumab. [1]
Source used to check bevacizumab patent status
[1] https://www.drugpatentwatch.com/p/bevacizumab